Fig. 6From: Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS studyChange in MIDAS scores at 12 weeks by sex. MIDAS, Migraine Disability Assessment; LSM, least-squares mean; SE, standard error. aP = 0.023 vs placebo. bP = 0.004 vs placebo. cP < 0.001 vs placeboBack to article page